Introduction
Adult T-cell leukemia (ATL) is a disease entity with characteristic clinical and immunological features (Yodoi et al., 1974; Uchiyama et al., 1977) , caused by human T-cell leukemia virus type-I (HTLV-I; Yoshida et al., 1982) . The long latent period and the age-dependent accumulation of leukemogenic events within HTLV-Iinfected T cells suggest that the development of ATL is a multistep process (Okamoto et al., 1989; Matsuoka, 2003) . HTLV-I-infected T cells generally grow only in the presence of interleukin-2 (IL-2) (IL-2-dependent phase/ IL-2-dependent cells; Maeda, 1992) . But when these cells are cultured with IL-2 for several months, some fractions become able to proliferate continuously in the absence of IL-2 (IL-2-independent phase/IL-2-independent cells; Morgan et al., 1976) . The transition from the IL-2-dependent phase to IL-2-independent phase is an in vitro model for investigating the multistep process of the malignant transformation of HTLV-I-infected T cells (Maeda et al., 1985; Migone et al., 1995) . ATL-derived factor (ADF) was cloned from HTLV-I-infected T cells (Tagaya et al., 1989) and revealed to be a human homologue of thioredoxin (TRX; Holmgren, 1985) . TRX is an oxidoreductase with important regulatory roles in cell proliferation and signal transduction (Masutani and Yodoi, 2002) . TRX expression is markedly enhanced in HTLV-I-infected T cells (Makino et al., 1992) . Using the yeast two-hybrid screening system, we identified thioredoxin-binding protein-2 (TBP-2; Nishiyama et al., 1999) , which is identical to vitamin D 3 upregulated protein 1 (VDUP1; Chen and DeLuca, 1994) . We have reported that TBP-2 has growth suppressive activity (Nishinaka et al., 2004a) and its expression is abrogated in HTLV-I-infected IL-2-independent T cells, but maintained in HTLV-I-infected IL-2-dependent T cells as well as in HTLV-I-negative T cells (Nishinaka et al., 2004a) . TBP-2 expression is also downregulated in human cancers (Butler et al., 2002; Han et al., 2003) . However, the mechanisms for the downregulation of TBP-2 expression remain unaddressed. In this study, we have investigated the mechanism of loss of TBP-2 expression in IL-2-independent HTLV-I-infected T-cell lines. We have also analysed the role of TBP-2 in IL-2-dependent growth control in HTLV-I-infected T-cell lines.
Results
Treatment with a demethylating reagent 5-aza-2 0 -deoxycytidine (5-aza-CdR) restored TBP-2 mRNA expression in HTLV-I-infected IL-2-independent cells In the early stages of culture, HTLV-I-infected T cells generally grow only in the presence of IL-2 (IL-2-dependent cells). When these cells are cultured in the presence of IL-2 for several months; however, some fractions become able to proliferate continuously in the absence of IL-2 (IL-2-independent cells) (Morgan et al., 1976; Maeda, 1992) . Each set of IL-2-dependent and IL-2-independent cells has the same clonal origin as confirmed by the T-cell receptor-b gene rearrangement and HTLV-I proviral integration sites (Maeda, 1992) . We analysed the expression of TBP-2 mRNA in sets of IL-2-dependent and IL-2-independent cells. The expression was lost in IL-2-independent cells (ATL-2, ED-40515, ATL-35T and ATL-43T) but not in IL-2-dependent cells (Figure 1a ). However, we did not find genetic alterations in the promoter or coding region of the TBP-2 gene (data not shown). The TBP-2 promoter region nearest the TATA-box contained more than 49% GC and the observed CpG (number of CpG multiplied by total number of nucleotides of the region)/expected CpG (number of C multiplied by total number of nucleotides of the region) ratio was 0.64. The CpG/GpC ratio was 1. These values are considered sufficient to meet the criteria for CpG-dinucleotides susceptible to methylation (Gardiner-Garden and Frommer, 1987) . Since hyper-methylation of promoter CpG-dinucleotides is often associated with inactivation of gene transcription, we first examined whether the TBP-2 gene is methylated by testing the effect of a demethylating reagent, 5-aza-CdR, on TBP-2 expression in IL-2-independent ATL-43T and ATL-2 cells. Consistent with a previous report (Nosaka et al., 2000) , treatment with 5-aza-CdR restored CDKN2A gene expression ( Figure 1b , mid gel). The treatment also restored the mRNA expression of TBP-2 in the cells (Figure 1b, upper gel, and 1c) . To further examine the methylation status of the TBP-2 promoter region, we directly sequenced the genomic DNA after treatment with sodium bisulfite. Sodium bisulfite converts C to T, except the C of methylated CpG. As shown in Figure 2 , the CpGs in the promoter region and exon-1 of TBP-2 were heavily methylated in IL-2-independent ATL cell lines, compared with those in IL-2-dependent cell lines. On treatment with 5-aza-CdR, about one-third of the methylated CpGs were demethylated in IL-2-independent ATL-43T and ATL-2 cells. These results strongly suggested that DNA methylation is involved in the mechanism of abrogation of TBP-2 mRNA expression in HTLV-I-infected IL-2-independent cells.
Involvement of histone deacetylation in TBP-2 gene silencing in HTLV-I-infected IL-2-independent cells The restoration of TBP-2 expression by 5-aza-CdR in IL-2-independent cells seemed to be partial. Moreover, DNA methylation and histone deacetylation are dynamically linked and synergistically silenced tumor suppressor genes (Cameron et al., 1999) . Therefore, we next analysed whether histone deacetylation is involved in TBP-2 gene silencing. Treatment with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, alone was unable to restore TBP-2 expression in IL-2-independent ATL-43T and ATL-2 cells (Figure 3a) . Then, the cells were sequentially treated with 5-aza-CdR and SAHA. TBP-2 gene expression was restored by treatment with 5-aza-CdR (Figure 3b , mid gel). These results suggested that both DNA-methylation and histone deacetylation synergistically silence the TBP-2 gene in HTLV-Iinfected IL-2-independent cells. In an earlier report (Butler et al., 2002) , SAHA augmented TBP-2 expression through the CCAAT element of the TBP-2 promoter. However, SAHA alone was unable to restore the TBP-2 expression in our cases. To clarify whether the effect of SAHA is a cancellation of histone deacetylation, we performed a chromatin immunoprecipitation (Chip) assay in IL-2-independent ATL-43T and ATL-2 cells. The PCR signal obtained using antiacetylated-H3 or H4 antibody was very weak in IL-2-independent ATL-43T and ATL-2 cells, before treatment or on treatment with SAHA only (Figure 3c ). After treatment with 5-aza-CdR, the PCR signal was markedly enhanced. Sequential treatment with 5-azaCdR and SAHA further strengthened the PCR signal. These results strongly suggested that DNA methylation and histone deacetylation are synergistically involved in the TBP-2 gene silencing in HTLV-I-infected IL-2-independent cell lines.
Association between downregulation of TBP-2 expression in response to IL-2 and cellular growth Augmented TBP-2 expression results in growth suppression (Nishinaka et al., 2004a, b) . We then analysed the relation between TBP-2 expression and growth in response to IL-2. We examined the level of TBP-2 expression and cell growth using proliferated well regardless of IL-2. In these cells, TBP-2 expression was completely abrogated and the cell growth did not change in response to IL-2. In Figure 4e (ATL-43T) and Figure 5e (ATL-2), statistical analysis of the day-3 data showed a significant (Po0.05) difference in growth between the presence and absence of IL-2 in IL-2-dependent cells and sequentially treated IL-2-independent cells, but not in untreated IL-2-independent cells. These results suggested that restored TBP-2 expression is associated with the response to IL-2 and suppression of uncontrolled IL-2-independent growth. Ectopic expression of TBP-2 suppressed cell growth and partially restored IL-2 responsiveness To further analyse the role of TBP-2 in the response to IL-2, we utilized HTLV-I-transformed MT-2 cells ectopically expressing TBP-2 (Nishinaka et al., 2004a) . TBP-2 protein expression in these transfectants was confirmed (Figure 6a ). While the control clones C 1 and C 4 proliferated well regardless of IL-2, the TBP-2-overexpressing clones T 1 and T 2 proliferated less without IL-2 than with IL-2 (Po0.05; Figure 6b ). Addition of IL-2 suppressed the expression of TBP-2 in TBP-2-overexpressing clones T 1 and T 2 (Figure 6b ; Agarose gel snaps). These results suggested that the TBP-2 expression suppressed cell growth and partially restored responsiveness to IL-2. We further analysed the relationship between TBP-2 expression and IL-2-dependency in IL-2-dependent ATL-43T and ATL-2 cells by knocking down TBP-2 expression using RNA-interference (RNAi). The expression of TBP-2 was downregulated in these cells after the transfection with RNAi of TBP-2 but not with control RNAi (Figure 6c ). The cells transfected with nonsilencing control RNAi proliferated in the presence of IL-2 but not in the absence of IL-2, while those cells transfected with TBP-2 RNAi showed partial proliferation in the absence of IL-2 (Figure 6d ). These results suggest that loss of TBP-2 expression causes HTLV-I-infected IL-2-dependent cells to acquire a partial capability for growth without IL-2.
Discussion
We revealed that in IL-2-independent cells, the expression of TBP-2 is completely silenced due to DNA methylation and histone deacetylation (Figures 1-3) . DNA methylation and histone deacetylation with the downregulation of gene expression for tumor suppressors such as CDKN2A, p53, E-cadherin and VHL tumor suppressor have been also reported (Ushijima and Okochi-Takada, 2005) . TBP-2 is a regulator of the cell cycle and apoptosis (Butler et al., 2002; Nishinaka et al., 2004a) . The TBP-2 gene is downregulated during oncogenesis (Butler et al., 2002; Han et al., 2003) , reported as a suppressor of melanoma metastasis (Goldberg et al., 2003) , and implicated in tumor progression in TBP-2 knockout mice (Oka et al., in preparation). Therefore, the TBP-2 gene seems to be an onco-suppressive gene. An HDAC inhibitor, SAHA, did not augment TBP-2 expression alone but induced the expression only after the reversal of DNA methylation (Figure 3a and b) . Demethylation slightly induced histone acetylation (Figure 3c) . These results indicate a link between DNA methylation and histone deacetylation, consistent with previous reports (Coombes et al., 2003; Satoh et al., 2003) .
In HTLV-I-infected IL-2-dependent cells as well as murine IL-2-dependent CTLL-2 cells (data not shown), TBP-2 mRNA expression was upregulated on the deprivation of IL-2 and cells did not grow, whereas the expression was downregulated to within the normal range on the addition of IL-2 and cells started to grow, as shown by the current study and elsewhere (Nishinaka et al., 2004a) . TBP-2 gene expression is also induced by treatment with vitamin D 3 (Chen and DeLuca, 1994 ), HDAC inhibitors (Butler et al., 2002) , and serum deprivation (Han et al., 2003) . Therefore, expression of the TBP-2 gene seems to be transcriptionally induced under conditions associated with cell growth arrest. TBP-2 mRNA expression paralleled the protein level (Nishinaka et al., 2004a) . The level of TBP-2 showed an inverse correlation with cell growth in response to IL-2 (Figure 4 and 5). TBP-2 may play a key role in the regulation of IL-2-dependent growth. TBP-2 gene regulation seems to be a sensor of deprivation of IL-2 signal. IL-2 deprivation upregulates TBP-2 expression transcriptionally, leading to cell growth arrest. Addition of IL-2 to the IL-2-deprived cells downregulates the expression of TBP-2 to the basal level, leading to proliferation. Therefore, loss of TBP-2 or loss of TBP-2 gene regulation causes loss of the growth control mechanism.
The ectopic expression of TBP-2 in MT-2 cells (Figure 6a ) suppressed cell growth and restored the responsiveness to IL-2, although the response was partial (Figure 6b) . Similarly, knockdown of TBP-2 by RNAi in IL-2-dependent cells (Figure 6c ) caused a partial loss of IL-2-dependent growth control (Figure 6d) . We consider the reason why TBP-2 overexpression only partially restored IL-2 dependence to be as follows. Since the transformation of HTLV-I seems to be a multistep process, TBP-2 alone may not be enough to restore the dependence on IL-2. In addition, the overexpressed TBP-2 gene is less responsive to exogenous stimuli such as IL-2. The gene regulation of TBP-2 expression may be important for full IL-2-dependence. Overexpression of TBP-2 did not change the expression of the IL-2 receptor, or STAT binding activity (data not shown). Further study is needed to elucidate the mechanism of the regulation of TBP-2 expression in response to IL-2. The mechanism by which TBP-2 regulates growth suppression is under investigation. In our previous report, we observed a similar growth suppressive effect on overexpression of TBP-2 in other HTLV-I-transformed T cells (IL-2-independent ATL-43 T, ATL-2, and MT-2 cells). We also reported the disappearance of TBP-2 expression in Hut-102, ATL-2, MT-1 and MT-2 cells (Nishinaka et al., 2004a) , showing the generality of the finding in HTLV-Iinfected cells. Loss of TBP-2 expression may augment the reducing activity of TRX (Nishiyama et al., 1999) , enhancing the growth of HTLV-I-infected T cells. In MT-2 cells ectopically expressing TBP-2, the expression of p16 was augmented (Nishinaka et al., 2004a) . Overexpression of TBP-2 also suppressed cell growth in MCF-7 cells, in which the p16 gene is deleted (Nishinaka et al., 2004b) , suggesting that there are other mechanisms to suppress cell growth. Analyses of gene expression in TBP-2 knockout cells using Gene chips are underway. TBP-2 is localized to the nuclear compartment (Nishinaka et al., 2004b) . The interaction of TBP-2 with transcriptional repressors such as Fanconi anemia zinc-finger (FAZF), promyelocytic leukemia zinc-finger (PLZF) and HDAC1 has been suggested (Han et al., 2003) , and we have isolated several nuclear proteins that are important for the regulation of transcriptional events as partners of TBP-2 (Masutani et al., in preparation) . Therefore, it could be speculated that TBP-2, augmented by various stimuli, interacts with growth controlling molecules such as an HDAC complex to induce cell growth arrest.
In summary, we showed that the TBP-2 gene is silenced due to DNA-methylation and histone deacetylation in IL-2-independent cell lines and that TBP-2 expression is closely associated with responsiveness to IL-2-dependent growth. The complete silencing of the TBP-2 gene is seen in HTLV-I-infected IL-2-independent cells but not in other T-cell lines (Nishinaka et al., 2004a) , EBV-transformed cell lines, and other cell lines (unpublished observation). Therefore, the silencing may be specifically linked to the HTLV-I infection. Therefore, the role of the loss of TBP-2 expression seems more important in HTLV-I-infected leukemic cells. Although TBP-2 expression does not seem to be associated with Tax expression in the HTLV-I infected cell lines (data not shown), the role of viral proteins including Tax should be examined further. Clastogenetic changes (point mutations, deletions, substitutions, and translocations) are frequently found in HTLV-I-transformed cells. Disruption of base excision repair, nucleotide excision repair, DNA end stability, telomerase and cell cycle progression leads to an increase in the frequency of genomic mutation. ATL cells are convoluted and known to be aneuploid, suggesting an abnormality of the mitosis checkpoint in HTLV-I transformation (Jeang et al., 2004) . These aspects of HTLV-I transformation and ATL leukemogenesis are important. The role of loss of TBP-2 in these aspects of HTLV-I transformation should be also investigated further.
Materials and methods

Cell culture and transfections
Human lymphocytic leukemia T cells (Jurkat) and HTLV-Iinfected T cells (ATL-2, MT-2, ED-40515, ATL-35T and ATL-43T) were cultured in RPMI-1640 medium containing 10% heat inactivated fetal calf serum (FCS) and antibiotics (penicillin 100 U/ml and streptomycin 100 mg/ml) at 371C with 5% CO 2 in air. For the maintenance of IL-2-dependent HTLV-I-infected T cells, IL-2 (7.5 ng/ml; Peprotech EC) was added to the culture medium. HTLV-I-infected IL-2-dependent T cells, such as ATL-2, ED-40515, ATL-35T and ATL-43T), were established from ATL patients by culture in the presence of IL-2, whereas IL-2-independent cells were established by the long-term culture of IL-2-dependent cells (Maeda, 1992) . Each set of IL-2-dependent and IL-2-independent cells has the same clonal origin as confirmed by the T-cell receptor-b gene rearrangement and HTLV-I proviral integration sites (Maeda, 1992) . Stable MT-2 transfectants overexpressing TBP-2 were generated as described previously (Nishinaka et al., 2004a) and maintained in medium containing 2 mg/ml of G418 (Nacalai Tesque).
Treatment of cells with 5-aza-CdR or SAHA For the treatment with a demethylating reagent, IL-2-independent ATL-43T and ATL-2 cells were cultured in medium supplemented with 1 mM 5-aza-CdR (Sigma) for 3 or 5 days. For the treatment with HDAC inhibitors, cells were cultured in medium supplemented with 2.5 mM SAHA (Alexis Biochemicals). For the sequential treatment with the demethylating reagent and HDAC inhibitors, the cells were cultured in medium supplemented with 1 mM 5-aza-CdR for the first 3 days, then with 2.5 mM SAHA for the next 24 h. After the sequential treatment, the cells were cultured in the presence or absence of IL-2 (1U) for an additional 3 days. SAHA was dissolved in dimethyl sulfoxide (DMSO). After each treatment, cells were placed in fresh medium.
Measurement of TBP-2 mRNA expression by RT-PCR
For the TBP-2 mRNA expression analyses, total RNA was isolated from the cells using Trizol reagent (Invitrogen). cDNA was synthesized using a SuperScript First-Strand Synthesis System (Invitrogen) with oligo dT [12] [13] [14] [15] [16] [17] [18] . The cDNA was amplified by PCR using a KlenTaq-LA DNA polymerase mix (Sigma). The primers used for the amplification were as follows: TBP-2, 5 0 -CCATGGTGATGTTCAAGAAGAT CAAG-3 0 (forward) and 5 0 -CTCAGGGGCATACATAAA GA-3 0 (reverse); TRX, 5 0 -ATGGTGAAGCAGATCGAG-3 0 (forward) and 5 0 -TTAGACTAATTCATTAATGGT-3 0 (reverse); CDKN2A, 5 0 -TTCGGCTGACTGGCTGGCCA-3 0 (forward; exon 1) and 5 0 -AGCTCCTCAGCCAGGTCCAC-3 0 (reverse; exon 2); and glyceraldehydes-3-phosphate dehydrogenase (GAPDH), 5 0 -ATGGGGAAGGTGAAGGTCGGAG TC-3 (forward) and 5 0 -CCATGCCAGTGAGCTTCCCGTT C-3 0 (reverse). PCR was performed under the following conditions: 32 cycles for TBP-2 (denaturing at 941C for 30 s, annealing at 531C for 1 min, and extension at 721C for 2 min), 20 cycles for TRX (denaturing at 941C for 30 s, annealing at 501C for 30 s, and extension at 721C for 1 min), 30 cycles for CDKN2A (denaturing at 941C for 30 s, annealing at 611C for 45 s, and extension at 721C for 1 min), and 22 cycles for GAPDH (denaturing at 941C for 30 s, annealing at 611C for 1 min, and extension at 721C for 90 s). The PCR products were visualized by electrophoresis in 3% NuSieve GTG agarose (Cambrex Bio Science) gel.
Quantitative real-time RT-PCR For measurement of the quantity of TBP-2 mRNA, real-time RT-PCR was conducted with a TaqMan Universal Master Mix (Applied Biosystems) using reverse transcribed cDNA as a template, in triplicate. The amplification was performed using an ABI Prism7000 under the following conditions: 501C for 2 min and 951C for 10 min, followed by 40 cycles (951C for 15 s and 601C for 1 min). The oligos and TaqMan probe for TBP-2 were purchased from Applied Biosystems. 18S ribosomal RNA was used as an internal control.
Sodium bisulfite sequencing of genomic DNA The genomic DNA was prepared from HTLV-I-infected IL-2-dependent or -independent cells using a Puregene DNA isolation kit (Gentra). Sodium bisulfite treatment was performed as reported previously (Nosaka et al., 2000; Yasunaga et al., 2004) . For the sequencing of the TBP-2 promoter region, 100 ng of genomic DNA was amplified by PCR using as primers, 5 0 -GGAGAAGACATCGGTCCT-3 0 (forward) and 5 0 -CATGATGGAACTGAGTTGGT-3 0 (reverse). For bisulfite-sequencing analyses, 100 ng of sodium bisulfite-treated genomic DNA was amplified by PCR using two pairs of methylation-specific primers. For the TATAbox region, a first round of amplification was performed with 5 0 -GGTTTTAGGGTTAGTGGGA-3 0 (forward) and 5 0 -AAAAACCTTCTTTCCCCCAA-3 0 (reverse), followed by a second round of nested PCR with 5 0 -TTTATTGGATTTGG GAGAA-3 0 (forward) and 5 0 -ATCCAATCTCCACAAACA CTCC-3 0 (reverse) primers. For the exon-1 region, a first round of amplification was performed with 5 0 -GGAAAGAA GGTTTTTTTTTTGA-3 0 (forward) and 5 0 -CCACTTACCT ATTAACTAATCT-3 0 (reverse), followed by a second round of nested PCR with 5 0 -TGATTTTGTTTAGTGTAATTAG-3 0 (forward) and 5 0 -CCTATTAACTAATCTTCCAA-3 0 (reverse). Amplification was carried out under the following conditions: 30 cycles (denaturing at 941C for 30 s, annealing at 531C for 1 min and extension at 721C for 2 min), followed by a final extension at 721C for 8 min. The PCR products were purified using a QIAEX II Gel extraction kit (Qiagen) and ligated into the vector pCR2.1 TOPO (Invitrogen). Inserts from five positive clones of each product were sequenced using M13 primers. Sequencing was performed using Big Dye Terminator reagent (Applied Biosystems) with an ABI PRISM310 Genetic Analyzer.
Chromatin immunoprecipitation (Chip) assay
For analyzing the histone acetylation status in TBP-2-restored cells, a Chip assay was performed as described previously (Spencer et al., 2003) . In brief, a chromatin solution was immunoprecipitated overnight at 41C, using antiacetylated H3 and H4 antibodies (Upstate Biotechnology). Precipitated DNA was analysed by PCR amplification, using a KlenTaq LA DNA Polymerase Mix (Sigma). The following promoterspecific primers were used: TBP-2 promoter region (207 bp); 5 0 -TCCAGAGCGCAACAACCAT-3 0 (forward) and 5 0 -AAG CAGGAGGCGGAAACGT-3 0 (reverse) or, b-globin promoter region (237 bp); 5 0 -GGCAAGGTGAACGTGGATG AAGTTGGTG-3 0 (forward) and 5 0 -GGAGTGGACAGA TCCCCAAAGGACTCAAAG-3 0 (reverse). PCR was carried out under the following conditions: 30 cycles for TBP-2 (denaturing at 951C for 30 s, annealing at 531C for 1 min, and extension at 721C for 2 min) or, 28 cycles for b-globin (denaturing at 951C for 30 s, annealing at 661C for 1 min, and extension at 721C for 2 min). The PCR products were visualized by electrophoresis in 3% NuSieve GTG agarose gel.
Western blot
Cell lysates were prepared with lysis buffer (150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 20 mM Tris-HCl (pH 7.5), 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM NaF and protease inhibitor cocktail (Roche)). Western blotting was performed as described previously (Nishinaka et al., 2004a) . The membrane was blocked with 10% (w/v) skim milk in Tris-buffered saline containing 0.05% Tween-20, then incubated with monoclonal anti-TBP-2 or anti-b-actin (Sigma, St MO) antibodies, followed by peroxidase-conjugated anti-mouse IgG (Amersham Biosciences, Tokyo, Japan). An ECL Western blot detection kit (Amersham, Tokyo, Japan) was used to visualize the epitopes.
Knockdown of TBP-2 expression by RNA interference (RNAi) Double stranded oligonucleotides (rACAGACUUCGGA GUACCUGdTT) for selective silencing of TBP-2 or control oligonucleotides (rUUCUCCGAACGUGUCACGUdTT) (Qiagen) were transfected into cells using a human T cell nucleofector kit (Amaxa biosystems, Tokyo, Japan). Eight hours after transfection, IL-2 was added to the culture.
Cell proliferation assay
To analyse the cellular growth, cell proliferation was assayed based on [ 3 H]-thymidine incorporation or with the MTT assay using WST-1 reagent (TaKaRa). Cells (2-5 Â 10
